Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods of treating cancer using Anti-pd-l1 antibodies and antiandrogens

A PD-L1, anti-androgen technology, applied in the direction of antibody medical components, chemical instruments and methods, antibodies, etc., can solve problems such as unsuitability, unsatisfied prostate cancer treatment options, failure of taxane regimens, etc.

Inactive Publication Date: 2019-10-22
F HOFFMANN LA ROCHE & CO AG
View PDF67 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] Given the limitations of the treatments currently available for patients with prostate cancer (e.g., mCRPC), especially those who have failed prior treatment with an androgen synthesis inhibitor and who have failed, are not suitable for, or refuse a taxane regimen , there remains an unmet need in the art for improved and tolerable treatment options for prostate cancer such as mCRPC

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of treating cancer using Anti-pd-l1 antibodies and antiandrogens
  • Methods of treating cancer using Anti-pd-l1 antibodies and antiandrogens

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0210] Example 1: Efficacy of anti-PD-L1 antibodies in combination with enzalutamide in patients with castration-resistant prostate cancer (CRPC)

[0211] To evaluate treatment with an anti-PD-L1 antibody (atezolizumab (MPDL3280A)) in combination with an antiandrogen (enzalutamide) compared to enzalutamide alone in patients with prostate cancer (e.g. CRPC (e.g. metastatic safety and efficacy in patients with recurrent or localized, inoperable CRPC)) enrolling patients in a phase III, multicenter, randomized, open-label study. To be eligible, patients must have (i) failed prior treatment with an androgen synthesis inhibitor for prostate cancer, such as CRPC (e.g., metastatic or locally limited, inoperable CRPC) (e.g., (e.g. abiraterone) treatment) and (ii) failure of treatment with a taxane regimen (e.g. taxane regimen for prostate cancer (e.g. metastatic hormone sensitive and / or CRPC (e.g. mrCPRC))), Ineligible for, or refused treatment with, a taxane regimen for prostate can...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the treatment of cancers, such as a prostate cancer (e.g., castration-resistant prostate cancer (CRPC)). More specifically, the invention concerns the treatment of human patients having a prostate cancer (e.g., CRPC, e.g., metastatic CRPC) with a combination therapy including an PD-1 axis binding antagonist and an antiandrogen.

Description

[0001] sequence listing [0002] This application, containing a Sequence Listing, has been filed electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on December 4, 2017, is named 50474-153WO2_Sequence_Listing_12.4.17_ST25 and is 9,553 bytes in size. [0003] field of invention [0004] The present invention relates to the treatment of cancer, such as prostate cancer (eg, castration-resistant prostate cancer (CRPC)). More specifically, the present invention concerns the combination of an anti-androgen (e.g. enzalutamide) and an anti-androgen (e.g. enzalutamide) by administering a PD-1 axis binding antagonist , for the treatment of human patients with prostate cancer, such as metastatic CRPC (mCRPC) or locally confined, inoperable CRPC. [0005] Background of the invention [0006] Cancer is characterized by the uncontrolled growth of subpopulations of cells. Cancer is the leading cause of death in the developed wor...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28A61K39/395A61K31/4166
CPCA61K39/39558A61K31/4166C07K16/28C07K16/2827A61K2039/505G01N2800/52A61K45/06A61P13/08A61P35/00A61P35/02A61P5/28A61K2300/00G01N33/6893G01N33/57434G01N33/57484A61K2039/54A61K2039/542A61K2039/545C07K14/70532C07K2317/524C07K2317/56
Inventor S·马里亚萨桑C·希夫S·纳拉亚南
Owner F HOFFMANN LA ROCHE & CO AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com